Last 47 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 2.35 | 11.11 | 15.36 | 0.79 | 4.85 | 1.43 | 7.14 | 5.26 | 5.78 | — | — | 85.90 | — | — | — | 37.50 | — | — | — | — | — |
| — | +678.5% | +115.2% | -85.0% | -16.1% | — | — | -93.9% | — | — | — | +129.1% | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.87 | 2.43 | 2.26 | 2.89 | 1.95 | 0.84 | 1.53 | 1.31 | 1.29 | 0.98 | 2.19 | 1.77 | 1.67 | 2.08 | 2.20 | 1.26 | 2.28 | 1.63 | 7.67 | 5.55 | 7.20 |
| — | +190.8% | +47.7% | +120.1% | +51.3% | -14.6% | -30.2% | -25.7% | -22.9% | -53.0% | -0.1% | +39.8% | -26.5% | +27.7% | -71.4% | -77.2% | -68.4% | -76.8% | +312.9% | -30.7% | +30.6% | |
| P/B Ratio | 2.20 | 1.80 | 1.33 | 2.06 | 4.61 | 4.15 | 17.60 | 92.01 | — | — | — | — | — | — | — | — | — | — | 75.55 | 14.93 | 12.49 |
| — | -56.7% | -92.4% | -97.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +882.4% | -14.2% | +57.0% | |
| P/FCF | 11.18 | 6.24 | 48.84 | 9.17 | 5.65 | 2.78 | — | 5.22 | 3.29 | 450.79 | — | — | — | 9.44 | — | — | — | — | — | — | — |
| — | +124.2% | — | +75.6% | +71.5% | -99.4% | — | — | — | +4675.8% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 6.71 | 7.62 | 11.09 | 8.62 | 4.78 | 1.41 | 6.40 | 4.43 | 5.01 | 39.75 | — | 31.07 | — | — | — | 29.24 | — | — | — | — | — |
| — | +441.0% | +73.4% | +94.6% | -4.6% | -96.5% | — | -85.7% | — | — | — | +6.3% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 6.84 | 7.64 | 10.57 | 8.39 | 4.70 | 1.41 | 6.40 | 4.45 | 5.08 | 42.17 | — | 26.55 | — | — | — | 27.55 | — | — | — | — | — |
| — | +443.6% | +65.2% | +88.6% | -7.4% | -96.7% | — | -83.2% | — | — | — | -3.6% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.3% | 89.2% | 92.2% | 91.5% | 93.2% | 95.6% | 91.7% | 89.9% | 85.5% | 92.4% | 93.1% | 89.4% | 95.5% | 96.0% | 96.3% | 99.3% | 98.9% | 96.5% | 99.3% | 97.6% | 99.3% |
| — | -6.7% | +0.5% | +1.7% | +9.0% | +3.5% | -1.5% | +0.6% | -10.5% | -3.8% | -3.2% | -10.0% | -3.4% | -0.5% | -3.0% | +1.8% | -0.4% | -3.0% | -0.3% | -0.7% | +0.1% | |
| Operating Margin | 42.6% | 30.0% | 20.2% | 33.2% | 40.9% | 60.1% | 23.9% | 28.9% | 25.4% | 1.2% | -23.6% | 5.5% | -15.9% | -19.6% | -48.8% | 4.1% | -82.1% | -43.5% | -156.9% | -104.9% | -91.8% |
| — | -50.2% | -15.6% | +14.8% | +61.0% | +4852.6% | +201.5% | +426.5% | +260.1% | +106.2% | +51.7% | +35.5% | +80.7% | +54.9% | +68.9% | +103.9% | +10.6% | +12.5% | -404.5% | -2.8% | -22.5% | |
| Net Margin | 124.7% | 22.0% | 14.7% | 384.0% | 40.2% | 58.6% | 21.5% | 24.9% | 22.5% | -2.8% | -27.9% | 2.1% | -20.2% | -24.5% | -51.9% | 2.7% | -84.9% | -45.2% | -164.0% | -110.9% | -97.3% |
| — | -62.5% | -31.4% | +1442.4% | +78.8% | +2196.9% | +176.9% | +1109.2% | +211.0% | +88.6% | +46.2% | -24.6% | +76.2% | +45.7% | +68.3% | +102.5% | +12.7% | +14.0% | -436.4% | -6.4% | -26.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 185.9% | 4.2% | 2.2% | 105.3% | 28.0% | 118.6% | 104.7% | 436.2% | — | — | — | — | — | — | — | — | — | -864.6% | -147.7% | -56.6% | -35.6% |
| — | -96.5% | -97.9% | -75.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | -4479.4% | -310.0% | -25.0% | -43.3% | |
| ROA | 108.3% | 3.4% | 1.7% | 70.9% | 12.4% | 31.2% | 6.7% | 9.5% | 9.3% | -0.8% | -6.8% | 0.6% | -4.9% | -5.5% | -10.5% | 1.1% | -15.6% | -9.7% | -17.3% | -12.8% | -10.8% |
| — | -89.2% | -74.8% | +650.0% | +33.9% | +3955.1% | +199.5% | +1391.6% | +289.4% | +85.3% | +35.5% | -43.5% | +68.7% | +43.7% | +39.5% | +108.8% | -44.8% | -47.1% | -171.7% | +22.4% | +0.6% | |
| ROIC | 45.8% | 4.3% | 2.2% | 6.5% | 19.4% | 74.2% | 47.4% | 6138.2% | — | — | -434.8% | — | — | — | — | — | — | -77.7% | -63.2% | -34.1% | -42.2% |
| — | -94.2% | -95.4% | -99.9% | — | — | +110.9% | — | — | — | — | — | — | — | — | — | — | -350.7% | -239.3% | -18.8% | -156.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.09 | 0.11 | 0.14 | 0.52 | 0.75 | 3.29 | 18.24 | — | — | — | — | — | — | — | — | — | — | 5.61 | 1.01 | 0.66 |
| — | -87.4% | -96.5% | -99.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +1085.5% | -12.4% | -18.2% | |
| Debt / EBITDA | 0.42 | 1.64 | 3.66 | 2.24 | 2.10 | 0.99 | 4.57 | 3.47 | 4.11 | 56.92 | — | 26.82 | — | — | — | 17.58 | — | — | — | — | — |
| — | +65.4% | -19.8% | -35.5% | -48.9% | -98.3% | — | -87.0% | — | — | — | +52.5% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.42 | 1.95 | 2.62 | 2.42 | 2.28 | 2.02 | 2.20 | 2.13 | 1.96 | 1.62 | 1.26 | 1.86 | 1.97 | 2.29 | 2.35 | 1.78 | 2.34 | 2.19 | 2.35 | 2.43 | 2.89 |
| — | -3.9% | +18.9% | +13.4% | +16.1% | +25.3% | +74.1% | +14.5% | -0.4% | -29.6% | -46.2% | +4.8% | -15.8% | +4.5% | +0.2% | -26.9% | -19.0% | -29.1% | -38.0% | +11.6% | -1.2% | |
| Quick Ratio | 2.30 | 1.79 | 2.48 | 2.30 | 2.06 | 1.90 | 2.13 | 2.04 | 1.87 | 1.48 | 1.17 | 1.76 | 1.84 | 2.05 | 2.11 | 1.64 | 2.19 | 2.08 | 2.23 | 2.33 | 2.77 |
| — | -5.7% | +16.7% | +13.0% | +9.9% | +28.9% | +81.5% | +15.9% | +1.6% | -27.8% | -44.3% | +7.5% | -15.7% | -1.6% | -5.6% | -29.6% | -21.0% | -30.2% | -38.8% | +8.8% | -3.2% | |
| Interest Coverage | 17.64 | 31.28 | 9.13 | 14.37 | 15.58 | 33.01 | 7.21 | 8.79 | 7.03 | 0.49 | -3.40 | 1.39 | -2.00 | -2.54 | -10.24 | 2.27 | -22.05 | -22.71 | -21.78 | -16.48 | -15.01 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RIGL stock.
Rigel Pharmaceuticals, Inc.'s current P/E is 2.3x. The average P/E over the last 4 quarters is 8.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Rigel Pharmaceuticals, Inc.'s current operating margin is 42.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Rigel Pharmaceuticals, Inc.'s business trajectory between earnings reports.